Dorzolamide/timolol

Last updated

Dorzolamide hydrochloride/Timolol maleate eye drops
Combination of
Dorzolamide hydrochloride Carbonic anhydrase inhibitor
Timolol maleate Beta blocker
Clinical data
Trade names Cosopt, others
AHFS/Drugs.com FDA Professional Drug Information
License data
Routes of
administration 		Eye drop
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
CompTox Dashboard (EPA)
   (verify)

Dorzolamide/timolol, sold under the brand name Cosopt among others, is a medication used to treat high pressure inside the eye including glaucoma. [3] [4] [5] It is a combination of dorzolamide hydrochloride and timolol maleate. [3] It may be used when a beta blocker, like timolol, is not sufficient alone. [6] It is used as an eye drop. [3]

Contents

Common side effects include eye discomfort, eye redness, taste changes, and blurry vision. [3] Serious side effects may include allergic reactions and heart failure. [3] Use is not recommended in those with asthma, a sulfonamide allergy, or a slow heart rate. [3] [6] Dorzolamide is a carbonic anhydrase inhibitor and timolol is a beta blocker. [3] Both work by decreasing the amount of aqueous humor made by the eye. [3]

The combination was approved for medical use in the United States in 1998. [3] It is available as a generic medication. [6] In 2020, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions. [7] [8]

Adverse effects

Common adverse effects include temporarily blurred vision, cloudy vision, double vision, temporary burning/stinging/itching of the eye, watery eyes, feeling as if something is in the eye, drooping eyelid, sensitivity to light, cough, flu symptoms, nausea, and stomach pain. [9]

More serious adverse effects include dizziness, slow or irregular heartbeat, muscle weakness, mental/mood changes, and coldness/numbness/pain in the hands or feet. [9]

Pharmacology

Dorzolamide is a human carboanydrase II inhibitor. [10] Inhibition of carboanhydrase in the ciliary processes of the eye decreases aqueous humor secretion supposedly by decreasing the formation rate of bicarbonate ions. [11] This results in reduction in both sodium and fluid transport.

Timolol is a non-selective beta-adrenergic antagonist. [12]

Comparison to other products

Despite each of the active ingredients being availed in their own respective formulations, combination formulations are typically more convenient for the patient without sacrificing any quality in therapy. In the case of Cosopt, the combination formulation dosed twice daily provides equivalent treatment to both dorzolamide 2% dosed two times daily and timolol 0.5% dosed three times daily. [13] Specifically, the mean reduction in intraocular pressure was 27.4% for the combination product, 15.5% for dorzolamide 2%, and 22.2% for timolol 0.5%.

Compared to other products such as latanoprost, both are equally efficacious with regard to lowering intraocular pressure and getting patients to reach their target intraocular pressure. [13] Cosopt, though, is typically less well tolerated than other treatments due to a well documented feeling of ocular burning upon administration.

History

Cosopt gained Food and Drug Administration (FDA) approval in April 1998 and was supplied initially by Merck. [14] In 2016, Merck & Co. had $95.3 billion in total assets, $40.3 billion in total equity, $24.3 billion in long term debt, and $13.4 billion in working capital. [15] This same year Merck & Co spent $20 billion total split virtually evenly between research and development (R&D) and marketing efforts.  Cosopt had annual sales of $342 million during the 12 months before June 2008. [16] In September 2013,  Merck & Co. sold the U.S. rights to their ophthalmic product line (including Cosopt) to Akorn Inc. for $52.8 million cash. [17]

Upon the original patent expiration, Hi-Tech Pharma was the first of many generic competitors to submit an abbreviated new drug application (ANDA) for dorzolamide hydrochloride/timolol maleate eye drops. [18] Hi-Tech Pharma's ANDA was approved on 28 October 2008.  At the time, controversy surrounded the approval of this first ANDA.  Hi-Tech sued the FDA for their right to 180 market exclusivity as laid out in the Hatch-Waxman Act. Apotex, another firm seeking an ANDA approval for generic Cosopt, argued that Hi-Tech "forfeited its rights to market exclusivity because it has failed to market the drug within 30 months of its ANDA submission or within 75 days after Merck withdrew its patent information." [18] The FDA upheld their previous exclusivity decisions on acarbose and granisetron, allowing both Hi-Tech and Apotex to make a generic version of Cosopt. [16] Soon after, ANDAs from Sandoz, Bausch & Laumb, TEVA and others were also approved. [19]

Just over a year before Merck sold their ophthalmic line to Akorn, Akorn developed a new formulation of dorzolamide hydrochloride/timolol maleate called Cosopt PF, which is simply a preservative free formulation of Cosopt. [20]

Related Research Articles

<span class="mw-page-title-main">Generic drug</span> Pharmaceutical equivalent to a brand-name product

A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same, the medical profile of generics is equivalent in performance compared to their performance at the time when they were patented drugs. A generic drug has the same active pharmaceutical ingredient (API) as the original, but it may differ in some characteristics such as the manufacturing process, formulation, excipients, color, taste, and packaging.

<span class="mw-page-title-main">Pilocarpine</span> Medication used to treat glaucoma and dry mouth

Pilocarpine is a medication used to reduce pressure inside the eye and treat dry mouth. As an eye drop it is used to manage angle closure glaucoma until surgery can be performed, ocular hypertension, primary open angle glaucoma, and to constrict the pupil after dilation. However, due to its side effects it is no longer typically used for long-term management. Onset of effects with the drops is typically within an hour and lasts for up to a day. By mouth it is used for dry mouth as a result of Sjögren syndrome or radiation therapy.

<span class="mw-page-title-main">Phenylephrine</span> Decongestant medication

Phenylephrine is a medication used as a decongestant for uncomplicated nasal congestion, used to dilate the pupil, used to increase blood pressure, and used to relieve hemorrhoids. It can be taken by mouth, as a nasal spray, given by injection into a vein or muscle, or applied to the skin.

<span class="mw-page-title-main">Betaxolol</span> Chemical compound

Betaxolol is a selective beta1 receptor blocker used in the treatment of hypertension and angina. Being selective for beta1 receptors, it typically has fewer systemic side effects than non-selective beta-blockers, for example, not causing bronchospasm as timolol may. Betaxolol also shows greater affinity for beta1 receptors than metoprolol. In addition to its effect on the heart, betaxolol reduces the pressure within the eye. This effect is thought to be caused by reducing the production of the liquid within the eye. The precise mechanism of this effect is not known. The reduction in intraocular pressure reduces the risk of damage to the optic nerve and loss of vision in patients with elevated intraocular pressure due to glaucoma.

<span class="mw-page-title-main">Timolol</span> Chemical compound

Timolol is a beta blocker medication used either by mouth or as eye drops. As eye drops it is used to treat increased pressure inside the eye such as in ocular hypertension and glaucoma. By mouth it is used for high blood pressure, chest pain due to insufficient blood flow to the heart, to prevent further complications after a heart attack, and to prevent migraines.

<span class="mw-page-title-main">Brimonidine</span> Chemical compound

Brimonidine is an α2 agonist medication used to treat open-angle glaucoma, ocular hypertension, and rosacea. In rosacea it improves the redness. It is used as eye drops or applied to the skin.

<span class="mw-page-title-main">Brinzolamide</span> Chemical compound

Brinzolamide is a carbonic anhydrase inhibitor used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

<span class="mw-page-title-main">Dorzolamide</span> Chemical compound

Dorzolamide, sold under the brand name Trusopt among others, is a medication used to treat high pressure inside the eye, including in cases of glaucoma. It is used as an eye drop. Effects begin within three hours and last for at least eight hours. It is also available as the combination dorzolamide/timolol.

<span class="mw-page-title-main">Levobunolol</span> Chemical compound

Levobunolol is a non-selective beta blocker. It is used topically in the form of eye drops to manage ocular hypertension and open-angle glaucoma.

<span class="mw-page-title-main">Bimatoprost</span> Chemical compound

Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.

Naphazoline/pheniramine, sold under the brand name Naphcon-A among others, is a combination eye drop used to help the symptoms of allergic conjunctivitis such as from hay fever. It contains naphazoline and pheniramine. It is used as an eye drop. Use is not recommended for more than three days.

<span class="mw-page-title-main">Levobetaxolol</span> Chemical compound

Levobetaxolol is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is marketed as a 0.25 or 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor.

<span class="mw-page-title-main">Nepafenac</span> NSAID analgesic and anti-inflammatory drug

Nepafenac, sold under the brand name Nevanac among others, is a nonsteroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop 0.1% solution (Nevanac) or 0.3% solution (Ilevro). It is used to treat pain and inflammation associated with cataract surgery. Nepafenac is a prodrug of amfenac, an inhibitor of COX-1 and COX-2 activity.

Brimonidine/timolol, sold under the brand name Combigan among others, is a fixed-dose combination medication eye drop used for the treatment of glaucoma. It is a combination of brimonidine and timolol.

Ripasudil, a derivative of fasudil, is a rho kinase inhibitor drug used for the treatment of glaucoma and ocular hypertension.

Akorn Operating Company LLC was an American generic pharmaceuticals manufacturer based in Lake Forest, Illinois. The company dealt in developing, manufacturing and marketing of generic and prescription drugs as well as animal and consumer health products. It was a component of the NASDAQ Biotechnology Index.

<span class="mw-page-title-main">Adrenocorticotropic hormone (medication)</span> Chemical compound

Adrenocorticotropic hormone is used as a medication and as diagnostic agent in the ACTH stimulation test.

<span class="mw-page-title-main">Netarsudil</span> Chemical compound

Netarsudil, sold under the brand name Rhopressa among others, is a medication for the treatment of glaucoma. In the United States, in December 2017, the Food and Drug Administration (FDA) approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension. The European Medicines Agency approved it in 2019 for the same uses under the brand name Rhokiinsa.

Bimatoprost/timolol, sold under the brand name Ganfort, is a medication for the treatment of certain conditions involving high pressure in the eyes, specifically open angle glaucoma and ocular hypertension. It is available as eye drops.

Travoprost/timolol, sold under the brand name Duotrav among others, is a fixed-dose combination medication used for the treatment of glaucoma. It contains travoprost and timolol maleate.

References

  1. ↑ "Cosopt- dorzolamide hydrochloride and timolol maleate solution/ drops". DailyMed. 2 December 2022. Archived from the original on 24 January 2022. Retrieved 7 June 2023.
  2. ↑ "Cosopt PF- dorzolamide hydrochloride and timolol maleate solution/ drops". DailyMed. 8 November 2022. Retrieved 7 June 2023.
  3. 1 2 3 4 5 6 7 8 9 "Dorzolamide Hydrochloride and Timolol Maleate Solution". DailyMed. Archived from the original on 27 March 2019. Retrieved 26 March 2019.
  4. ↑ He M, Wang W, Huang W (2013). "Efficacy and tolerability of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials". PLOS ONE. 8 (12): e83606. Bibcode:2013PLoSO...883606H. doi: 10.1371/journal.pone.0083606 . PMC   3859645 . PMID   24349536.
  5. ↑ Konstas AG, Schmetterer L, Katsanos A, Hutnik CM, Holló G, Quaranta L, et al. (January 2021). "Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future". Advances in Therapy. 38 (1): 24–51. doi:10.1007/s12325-020-01525-5. PMC   7854404 . PMID   33108623.
  6. 1 2 3 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1149. ISBN   9780857113382.
  7. ↑ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 7 October 2022.
  8. ↑ "Dorzolamide; Timolol - Drug Usage Statistics". ClinCalc. Archived from the original on 11 October 2022. Retrieved 7 October 2022.
  9. 1 2 "Common Side Effects of Cosopt (Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution) Drug Center - RxList". RxList. Archived from the original on 7 November 2017. Retrieved 30 October 2017.
  10. ↑ "Dorzolamide". www.drugbank.ca. Archived from the original on 2 July 2017. Retrieved 27 October 2017.
  11. ↑ "Cosopt - FDA prescribing information, side effects and uses". Drugs.com. Archived from the original on 7 November 2017. Retrieved 30 October 2017.
  12. ↑ "Timolol". www.drugbank.ca. Archived from the original on 28 October 2017. Retrieved 27 October 2017.
  13. 1 2 Bartlett J (2008). Clinical Ocular Pharmacology. Elsevier Health Sciences. p. 166. ISBN   978-0750675765.
  14. ↑ "Merck Receives FDA Approval to Market 'Cosopt'". www.newswise.com. Archived from the original on 21 October 2017. Retrieved 20 October 2017.
  15. ↑ "Merck Form 10-K" (PDF). Merck. Archived (PDF) from the original on 28 October 2017. Retrieved 27 October 2017.
  16. 1 2 "FDA Says Hi-Tech Forfeited Exclusivity; Way Paved for Approval of All Cosopt ANDAs". Leydig. 7 November 2008. Archived from the original on 28 October 2017. Retrieved 27 October 2017.
  17. ↑ "Akorn Acquires Three Branded Ophthalmic Products from Merck". Business Wire. 15 November 2013. Archived from the original on 28 October 2017. Retrieved 27 October 2017.
  18. 1 2 "Hi-Tech Sues FDA To Get Generic Cosopt Exclusivity". Law360. 4 August 2008. Archived from the original on 28 October 2017. Retrieved 27 October 2017.
  19. ↑ "Generic Cosopt Availability". Drugs.com. Archived from the original on 28 October 2017. Retrieved 27 October 2017.
  20. ↑ "October 2017 - When do the COSOPT PF patents expire, and when will generic COSOPT PF be available?". Deep knowledge on small-molecule drugs and the 120,000 global patents covering them. Archived from the original on 7 November 2017. Retrieved 29 October 2017.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.